| Japanese |
|---|
| Title | 新しい放射性医薬品による心臓核医学 |
|---|
| Subtitle | 総説 |
|---|
| Authors | 分校久志* |
|---|
| Authors(kana) | |
|---|
| Organization | *金沢大学医学部附属病院医療情報部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 31 |
|---|
| Number | 8 |
|---|
| Page | 1005-1010 |
|---|
| Year/Month | 1994/8 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」ここ数年の間に心臓核医学の分野では, 99mTc-MIBI, 99mTc-Tetrofosmin, 99mTc-Teboroxime(心筋血流), 111In抗ミオシン抗体(障害心筋), 123I-BMIPP(脂肪酸代謝), 123I-MIBG(交感神経機能)などの新しい放射性医薬品が導入されてきた. 99mTc血流製剤は画質の改善, 心機能・壁運動と血流の同時検査, SPECT撮像時間の短縮が可能である. 抗ミオシン抗体は特異的なイメージングが可能で各種心疾患での心筋壊死の評価への応用が期待される. BMIPPは従来SPECTで評価できなかった心筋エネルギー代謝の面からstunned myocardiumや心筋症など, 血流と代謝の乖離の評価が可能である. MIBGは虚血や不整脈をはじめ心臓交感神経の異常を伴う可能性のある種々の疾患での応用が始まっている. これらの新しい放射性医薬品は, 虚血性心疾患のみならず種々の心疾患において, 重症度や予後予測を含めたより詳細な病態生理の評価や病因の解明のためのツールとなることが期待される. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Nuclear cardiology, New radiopharmaceuticals, Myocardial perfusion, Metabolic imaging, Adrenergic imaging. |
|---|
| English |
|---|
| Title | Nuclear Cardiology with New Radiopharmaceuticals |
|---|
| Subtitle | |
|---|
| Authors | Hisashi BUNKO |
|---|
| Authors(kana) | |
|---|
| Organization | Department of Medical Informatics, Kanzawa University Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 31 |
|---|
| Number | 8 |
|---|
| Page | 1005-1010 |
|---|
| Year/Month | 1994/8 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] In the field of nuclear cardiology, 99mTc labeled myocardial perfusion agents such as MIBI, Tetrofosmin and Teboroxime, 111 In-antimyosin for imaging of myocardial necrosis, 123I-betamethyliodophenylpentadecanoic acid (BMIPP) for imaging of myocardial fatty acid metabolism and 123I-metaiodobenzyguanidine (MIBG) for imaging of myocardial adrenergic function are introduced recently in Japan. Improved image quality and simultaneous evaluation of myocardial perfusion, function and wall motion can be obtained with use of 99mTc labeled myocardial perfusion agents. 111 In-antimyosin enables specific imaging of myocardial necrosis which leads to the use for wide variety of heart diseases. Discrepancy of the myocardial perfusion and metabolism in case of stunned myocardium or cardiomyopathy can be evaluated by 123I-BMIPP in conjunction with perfusion agent. Recently wide variety of diseases which may have cardiac adrenergic abnormality are targeted for 123I-MIBG imaging. These new radiopharmaceuticals are expected to be powerful tool for evaluation of the pathophysiology including severity and prognosis and evaluation of the etiology of the various heart diseases. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Nuclear cardiology, New radiopharmaceuticals, Myocardial perfusion, Metabolic imaging, Adrenergic imaging. |
|---|